1. |
Stanworth SJ, Cockburn HA, Boralessa H, et al. Which groups of patients are transfused A study of red cell usage in London and southeast England. Vox Sang, 2002, 83(4):352-357.
|
2. |
Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des, 2005, 11(31):4099-4114.
|
3. |
龙村. 主编. 体外循环学. 北京: 人民军医出版社, 2004. 576-577.
|
4. |
Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canda. Transfus Med Rev, 2003, 17(2):120-162.
|
5. |
Caswell JE, Strange MB, Rimmer DM, et al. A novel hemoglobin-based blood substitute protects against myocardial reperfusion injury. Am J Physiol Heart Circ Physiol, 2005,288(4):H1796-1801.
|
6. |
Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med, 1996, 334(26):1685-1690.
|
7. |
Anbari KK, Garino JP, Mackenzie CF. Hemoglobin substitutes. Eur Spine J, 2004, 13( Suppl 1):S76-82.
|
8. |
Stowell CP, Levin J, Speiss BD, et al. Progress in the development of RBC substitutes, Transfusion, 2001, 41(2):287-299.
|
9. |
Greenburg AG, Kim HW. Hemoglobin-based oxygen carriers. Crit Care, 2004, 8(Suppl 2):S61-64.
|
10. |
Cohn SM. Blood substitutes in surgery. Surgery,2000,127(6): 599-602.
|
11. |
Winslow RM. Blood substitutes. Adv Drug Del Rev,2000,40(3):131-142.
|
12. |
Spahn DR, Pasch T. Physiological properties of blood substitutes. News Physiol Sci,2001,16(1):38-41.
|
13. |
Kim HW, Shen TJ, Sun DP, et al. A novel low oxygen affinity recombinant hemoglobin (alpha96val→Trp): switching quaternary structure without changing the ligation state. J Mol Biol, 1995, 248(4):867-882.
|
14. |
Conover CD, Malatesta P, Lejeune L, et al. The effects of hemodilution with polyethylene glycol bovine hemoglobin(PEG-Hb) in a conscious porine model. J Investig Med, 1996, 44 (5):238-246.
|
15. |
Hughes GS, Antal EJ, Locker PK , et al. Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med, 1996, 24(5):756-764.
|
16. |
Winslow RM. alpha-crosslinked hemoglobin: was failure predicted by preclinical testing Vox Sang, 2000, 79(1):1-20.
|
17. |
Winslow RM. Blood substitutes. Adv Drug Deliv Rev, 2000, 40(3):131-142.
|
18. |
赵明霞,龙村,贺学英,等. 兔体外循环中聚乙二醇牛血红蛋白偶联物对平均动脉压、胶体渗透压及p50的影响. 中华实验外科杂志, 2006, 23(9): 1044-1046.
|
19. |
LaMuraglia GM, O’Hara PJ, Baker WH, et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vasc Surg, 2000, 31(2):299-308.
|
20. |
Lamy ML, Daily EK, Brichant JF, et al. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology, 2000, 92(3):646-656.
|
21. |
Levy JH, Goodnough LT, Greilich PE, et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg, 2002, 124(1):35-42.
|
22. |
Hill SE, Gottschalk LI, Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth, 2002, 16(6):695-702.
|
23. |
Young MA, Riddez L, Kjellstrm BT, et al . MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med , 2005, 33(8): 1794-1804.
|
24. |
Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med, 2003, 348(15):1483-1485.
|
25. |
Gulati A, Sharma AC, Singh G. Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin. Crit Care Med, 1996, 24(1):137-147.
|
26. |
Cheng DC, Mazer CD, Martineau R, et al. A phase II dose-response study of hemoglobin raffimer (Hemolink) in elective coronary artery bypass surgery. J Thorac Cardiovasc Surg, 2004, 127(1):79-86.
|
27. |
Helm RE, Klemperer JD, Rosengart TK , et al. Intraoperative autologous blood donation preserves red cell mass but dose not decrease postoperative bleeding. Ann Thorac Surg, 1996, 62(5):1431-1441.
|
28. |
刘晋萍, 贺学英 , 龙村, 等. 聚乙二醇-牛血红蛋白在体外循环中对机体血流动力学变化的研究. 中国体外循环杂志, 2005, 3(3):157-160.
|
29. |
Mueller XM, Tevaearai HT, Jegger D, et al. Hemoglobin substitute and cardiopulmonary bypass. ASAIO J, 2000, 46(4):403-408.
|
30. |
Rajesh KG, Sasaguri S, Tian ZZ, et al. Potential role of mitochondrial permeability transition pore following long-time hypothermic heart preservation. Transplant Proc, 2002, 34(7):2645-2646.
|
31. |
Marinello E, Tabucchi A, Miraldi F, et al. Role of bovine hemoglobin enriched cardioplegia in myocardial preservation. Adv Exp Med Biol, 2000, 486:171-174.
|
32. |
Carlucci F, Miraldi F, Barretta A , et al. Preservation of myocardial energy status by bovine hemoglobin solutions during ischemia. Biomed Pharmacother, 2002, 56(5):247-253.
|
33. |
Serna DL, Powell LL, Kahwaji C, et al. Cardiac function after eight hour storage by using polyethylene glycol hemoglobin versus crystalloid perfusion. ASAIO J, 2000, 46(5):547-552.
|
34. |
Jones BU, Serna DL, Smulowitz P, et al. Extended ex vivo myocardial preservation in the beating state using a novel polyethylene glycolated bovine hemoglobin perfusate based solution. ASAIO J, 2003, 49(4):388-394.
|